About Us: Clinical Trials 

Retina Group of New England is proud to participate in the most cutting-edge research for vitreo-retinal diseases in Connecticut and Rhode Island. Our extensive work has attributed to some of the latest developments in retinal disease treatment. Based in New London, our research center conducts clinical trials for the treatment of diseases such as Wet Macular Degeneration, Dry Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusions.

 

Neovascular (Wet) Macular Degeneration  Treatment Treatment Status Vision Criteria
PANDA 2 Intravitreal Conversept Treatment Naive eye 20/32-20/320
GRAYBUG Intravitreal depot of Sunitinub Malate <18 mos, >3 injections 2 lines better
ARCHWAY Lucentis <9 mo, 3 injections or run in phase >20/200

 

Dry Macular Degeneration  Treatment Treatment Status Vision Criteria
SAGA ALK-001 ORAL Treatment Naive Eye >20/200
DERBY & OAKS Intravitreal APL Treatment Naive Eye > 20/320

 

Diabetic Retinopathy  Treatment Treatment Status Vision Criteria
RHINE Intravitreal faricimab 3 month washout  20/40-20/320
MYLAN (DME) Intravitreal Aflibercept biosimilar Treatment Naive 20/40-20/200

 

Retinal Vein Occlusion  Treatment Treatment Status Vision Criteria
TOPAZ Suprachoroidal steroid Treatment Naive Eye 20-70 letters on ETDRS

 

We are constantly investigating new treatment options. To participate in enrolling clinical trials, or for more information on the newest developments in retinal disease treatment/management, please contact our study coordinator, Emma at (860) 444-1292.

 

Clinical trials we previously participated in:

SCORE2 LTE – Standard of care for Retinal Vein Occlusion

PANORAMA – Intravitreal aflibercept vs Sham for Mild-Moderate NPDR

PANDA – Intravitreal Conversept vs. Aflibercept for Neovascular Macular Degeneration

TLC Study – Intravitreal ProDex for Retinal Vein Occlusion with Edema 2017-present (TLC)

Study of  Oral Emixustat Hydrochloride for Proliferative Diabetic Retinopathy 2017 (ACUCELA)

MAKO Study – Topical Squalamine Lactate for Neovascular (wet) Age-Related Macular Degeneration 2016-2017 (OHR)

ONYX Study  Intravitreal REGN910-3 for Neovascular (wet) Age-Related Macular Degeneration 2016-2017 (Regeneron)

RUBY Study – Intravitreal REGN910-3 for Diabetic Macular Edema 2016-2017 (Regeneron)

FILLY Study – Intravitreal APL-2 for Dry Age-Related Macular Degeneration with Geographic Atrophy 2015-2018 (Appelis)

Next study phase starting in summer of 2018

Panorama Study – Intravitreal Eylea to prevent progression of Diabetic Retinopathy 2015-present (Regeneron)

CAPELLA Study – Intravitreal REGN2176-3 for Neovascular (wet) Age-Related Macular Degeneration 2015-2017 (Regeneron)

APEX Study – Oral X82 for Neovascular (wet) Age-Related Macular Degeneration 2015-2018 (Tyrogenex)

Del Mar Study – Intravitreal Luminate for Diabetic Macular Edema 2015-2017 (Allegro)

Phase III study is coming

HAWK study – Intravitreal brolucizumab for Neovascular (wet) Age-Related Macular Degeneration 2015-2018 (Alcon)

Study results went to FDA for approval

DRCR Protocol U – Compared anti-VEGF and intravitreal corticosteroids+anti-VEGF for Diabetic Macular Edema 2015-2016

DRCR Protocol V – Compared treatments for Diabetic Macular Edema with good vision 2014-2017

DRCR Protocol T – Compared effectiveness of Avastin, Lucentis and Eylea for Diabetic Macular Edema 2012-2015

DRCR Protocol S – Compared Panretinal Photocoagulation and Lucentis for PDR 2012-2017

Based on study results Lucentis was FDA approved for Diabetic Retinopathy in 2017

SCORE2 Study and SCORE@ LTE – Compares intravitreal Eylea and Avastin for Central Retinal Vein Occlusion

1 year treatment and 4 years follow up 2014-present (EMMES)

SPECTRI Study – Intravitreal Lampalizumab for Dry Age-Related Macular Degeneration with Geographic Atrophy 2014-2018 (Genentech)

Eclipse and OPH1006 Studies – Intravitreal Fovista for Neovascular (wet) Age-Related Macular Degeneration 2013-2017 (Ophthotech)

Study of oral X82 for Neovascular (wet) Age-Related Macular Degeneration 2012-2015(tyrogenex)

VISTA Study – Intravitreal Eylea for Diabetic Macular Edema 2011-2014 (Regeneron)

Based on study results Eylea was FDA approved for Diabetic Macular Edema in 2014

SHORE Study – Intravitreal Lucentis for Edema secondary to Retinal Vein Occlusion 2011-2012 (Genentech)

COPERNICUS Study – Intravitreal Eylea for Central Retinal Vein Occlusion  2009-2012 (Regeneron)

Based on study results Eylea was FDA approved edema secondary to Central Retinal Vein Occlusion in 2012

RIDE Study – Intravitreal Lucentis for Diabetic Macular Edema 2007-2012 (Genentech)

Based on study results Lucentis was FDA approved for Diabetic Macular Edema in 2012

CRUISE Study – Intravitreal Lucentis for Central Retinal Vein Occlusion 2008-2009 (Genentech)

Based on study results Lucentis was approved by FDA for Retinal Vein Occlusion in 2010

BRAVO Study – Intravitreal Lucentis for Branch Retinal Vein Occlusion 2008-2009 (Genentech)

Based on study results Lucentis was approved by FDA for Retinal Vein Occlusion in 2010

HARBOR Study – Comparing regular and high dose of Intravitreal Lucentis for Neovascular (wet) Age-Related Macular Degeneration 2009-2012 (Genentech)

VIEW 1 Study – Intravitreal Eylea for Neovascular (wet) Age-Related Macular Degeneration 2008-2010 (Regeneron)

Eyelea was approved by FDA for Neovascular (wet) Age-Related Macular Degeneration based on this study results in 2011

FAME Study – Intravitreal insert of Fluocinolone acetonide  2006-2010 (Alimera)

Sustain release insert of FA was approved by FDA in 2014 for Diabetic Macular Edema

SAILOR Study  – Intravitreal Lucentis 2005-2006 (Genentech)

The only research site in South Eastern Connecticut that participated in this final study prior to FDA approval of  Lucentis for Neovascular (wet) Age-Related Macular Degeneration in June of 2006